
BIOTECH

SHOWCASE™ 2024

JANUARY 8-10, 2024

SAN FRANCISCO, CA, USA

ADDENDUM

Conference Update

Company Profile Corrections

Otovia Therapeutics
Funds Raised: \$9M to date

Presentation Time Changes

Bilix, Co., LTD is now presenting
Wednesday, Jan 9, at 9:30 AM in Yosemite A
Zenon Biotech is now presenting
Tuesday, January 9, at 4:30 PM in Franciscan C

Presenting Company Cancellations

Aeolian Biotech Corp
biotx.ai GmbH
Brinter Inc
Gyder Surgical Pty Ltd (DMS)
illumicell AI (SEED)
LexBio
Milk Care Co., Inc.

Additional Presenting Companies

Addex Therapeutics
Aliris
AutoMedicus Corporation
Auxilius Pharma
Bionomics Ltd
brain4care
ChainGen Biopharma Ltd
Circio AB
Coeurative, Inc.
Cognigenics, Inc.
Crossject SA
Dionysus Digital Health, Inc (SEED)
DsciLab Co. Ltd.
Elenae Therapeutics, Inc. (SEED)
Embold Therapeutics, Inc. (SEED)
Eugit Therapeutics Inc (SEED)
Espervita Therapeutics
GeneLancet Biosciences, Inc.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
iQure Pharma
Lactiga US, Inc.

Company and Presenter Title Changes

Acutis Diagnostic is now Acutis Biosciences and therapeutic focus is CRO, Analytical Pharma Services

NeuroTrauma Sciences
Neuvivo, Inc.
NXgenPort Inc (SEED)
OssiFi Therapeutics LLC
Rosebud Biosciences Inc. (SEED)
Vector BioMed

Lynk Pharmaceuticals Co., Ltd.
MEKanistic Therapeutics, Inc.
Modulus Therapeutics, Inc.
Narwhal Bio Inc. (SEED)
NGGT Inc.
Novel Biotechnology Inc. (SEED)
Papillon Biosciences, Inc. (SEED)
Pattern Computer
RND Pharmaceuticals Inc.
Sagmos Therapeutics
Sapphiros Ai Bio
SHIFTBIO INC.
Sinaptica Therapeutics Inc.
Trilo Therapeutics
TMAB Therapeutics, Inc. (SEED)
UgeneX Therapeutics
UltraSight (DMS)
VacV Biotherapeutics Limited
Variant Bio, Inc.
Westlake Genetech
YunQuan Biological Technology Co. (DMS)
Zenon Biotech

DMS=DigiMed Showcase

Additional Company Presentations:

Company Name	Presentation Date	Presentation Time	Presentation Location
Ultra Sight (DMS)	1/10/2024	11:30 AM	Yosemite A
YunQuan Biological Technology Co., Ltd. (DMS)	1/10/2024	2:15 PM	Yosemite A
Dionysus Digital Health, Inc (SEED)	1/10/2024	10:40 AM	Franciscan C
Elenae Therapeutics, Inc. (SEED)	1/10/2024	11:10 AM	Franciscan C
Embold Therapeutics, Inc. (SEED)	1/10/2024	10:30 AM	Franciscan C
Eugit Therapeutics Inc (SEED)	1/10/2024	11:20 AM	Franciscan C
Narwhal Bio Inc. (SEED)	1/10/2024	9:50 AM	Franciscan C
Novel Biotechnology Inc. (Digital) (SEED)	1/10/2024	10:50 AM	Franciscan C
Papillon Biosciences, Inc. (Digital) (SEED)	1/10/2024	11:30 AM	Franciscan C
TMAB Therapeutics, Inc. (SEED)	1/10/2024	11:00 AM	Franciscan C
Addex Therapeutics (SIX:ADXN)	1/8/2024	4:30 PM	Yosemite A
Aliris	1/10/2024	3:45 PM	Franciscan A
AutoMedicus Corporation	1/8/2024	2:15 PM	Franciscan B
Auxilius Pharma	1/8/2024	4:30 PM	Yosemite C
Bionomics Ltd (NASDAQ:BNOX)	1/9/2024	4:30 PM	Yosemite A
brain4care	1/8/2024	4:45 PM	Yosemite C
ChainGen Biopharma Ltd	1/10/2024	10:00 AM	Yosemite A
Circio AB	1/8/2024	2:30 PM	Yosemite C
Coeurative, Inc.	1/8/2024	11:15 AM	Franciscan D
Cognigenics, Inc.	1/10/2024	11:00 AM	Yosemite C
Crossject SA (Euronext:ALCJ)	1/9/2024	4:30 PM	Yosemite C
DsciLab Co.,Ltd.	1/10/2024	9:30 AM	Yosemite C
Espervita Therapeutics	1/10/2024	10:00 AM	Yosemite C
GeneLancet Biosciences, Inc.	1/10/2024	11:00 AM	Yosemite A
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX:1541)	1/10/2024	10:30 AM	Yosemite A
iQure Pharma	1/10/2024	11:15 AM	Yosemite A
Lactiga US, Inc.	1/10/2024	9:45 AM	Yosemite A
Lynk Pharmaceuticals Co., Ltd.	1/10/2024	10:15 AM	Yosemite C
MEKanistic Therapeutics, Inc.	1/10/2024	9:45 AM	Yosemite C
Modulus Therapeutics, Inc.	1/8/2024	3:30 PM	Yosemite C
NGGT Inc.	1/10/2024	2:00 PM	Yosemite A
Pattern Computer	1/10/2024	3:15 PM	Franciscan B
RND Pharmaceuticals Inc.	1/10/2024	11:45 AM	Yosemite A
Saghmos Therapeutics	1/10/2024	10:15 AM	Yosemite A
Sapphiros Ai Bio	1/10/2024	10:30 AM	Yosemite C
SHIFTBIO INC.	1/10/2024	11:30 AM	Yosemite C
Sinaptica Therapeutics Inc.	1/8/2024	4:00 PM	Yosemite C
Trilo Therapeutics	1/8/2024	2:00 PM	Franciscan C
UgeneX Therapeutics	1/10/2024	11:15 AM	Yosemite C
VacV Biotherapeutics Limited	1/10/2024	11:45 AM	Yosemite C
Variant Bio, Inc.	1/8/2024	4:15 PM	Yosemite C
Westlake Genetech	1/10/2024	10:45 AM	Yosemite C
Zenon Biotech	1/9/2024	4:30 PM	Franciscan C

DMS=DigiMed Showcase

Conference Update

Addex Therapeutics (SIX:ADXN) (In-Person)**Categorical Listings:** CNS-Neurological, Drug Discovery, Neurology**Location:** Geneva, Switzerland**Year Established:** 2002 **Website:** www.addextherapeutics.com**Corporate Partners:** Janssen Pharmaceuticals is developing the company's epilepsy program and Indivior is funding the company's GABAB PAM program for substance use disorders.**Funds Raised:** More than \$350K to date - \$100K venture; \$130K IPO; \$120K in multiple follow on offerings.**Presenter:** Tim Dyer, CEO**Aliris** (In-Person)**Categorical Listings:** Drug Delivery, Gene-Cell Therapy, Infectious Disease**Location:** Newark, Delaware United States**Year Established:** 2024 **Website:** INP**Corporate Partners:** None**Funds Raised:** Raising Seed round.**Presenter:** Jinlin Jiang, PhD, Co-Founder**AutoMedicus Corporation** (In-Person)**Categorical Listings:** Cardiovascular, Drug Delivery**Location:** Pasadena, California United States**Year Established:** 2014 **Website:**

www.automedicus.com/autopress

Corporate Partners: None to date.**Funds Raised:** Over \$600K self funded.**Presenter:** William Harrity, MD, Co-Founder & CMO**Auxilius Pharma** (In-Person)**Categorical Listings:** Cardiovascular**Location:** Hudson, Massachusetts United States**Year Established:** 2019 **Website:** www.auxiliuspharma.com**Corporate Partners:** AUX-001 has been developed in partnership with Netherlands-based formulating lab Avivia. CTM for Phase 1a has been manufactured by Germany-based Aenova Group.

Regulatory plan was developed by Premier Consulting.

Funds Raised: \$2.75M to date from individual investors and EU based early stage VCs.**Presenter:** Uwe Tigör, MD, CMO**Bionomics Ltd (NASDAQ:BNOX)** (In-Person)**Categorical Listings:** CNS-Neurological**Location:** Weston, United States**Year Established:** 1996 **Website:** www.bionomics.com.au**Corporate Partners:** Bionomics has a strategic partnership with Merck & Co., Inc. with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer's disease and other CNS conditions.**Funds Raised:** \$35M since Dec 2021.**Presenter:** Spyros Papapetropoulos, MD, PhD, President & CEO**brain4care** (In-Person)**Categorical Listings:** Artificial Intelligence (AI), CNS-Neurological, Diagnostics**Location:** Johns Creek, Georgia United States**Year Established:** 2017 **Website:** brain4.care/en/home-english**Corporate Partners:** There are no corporate partners at this stage. Looking for one or more to accelerate US market penetration.**Funds Raised:** \$17.3M in the last five years from friends and family offices.**Presenter:** Carlos Bremer, PhD, President, North America Division**ChainGen Biopharma Ltd** (In-Person)**Categorical Listings:** CNS-Neurological, Drug Delivery, Orphan-Rare Disease**Location:** Shanghai, China**Year Established:** 2022 **Website:** INP**Corporate Partners:** Biorecinn Inc., GenScript ProBio**Funds Raised:** Seed round \$6.5M in 2022.**Presenter:** Xuefeng Zhang, Co-Founder & COO**Circio AB** (In-Person)**Categorical Listings:** Immunology, Orphan-Rare Disease**Location:** Hässelby, Sweden**Year Established:** 2022 **Website:** www.circio.com**Corporate Partners:** INP**Funds Raised:** INP**Presenter:** Lubor Gaal, PhD, CFO**Coeurative, Inc.** (Virtual)**Categorical Listings:** Cardiovascular, Drug Discovery**Location:** Roanoke, Virginia United States**Year Established:** 2012 **Website:** www.coeurative.com**Corporate Partners:** INP**Funds Raised:** INP**Presenter:** John F. Schmedtje, Jr., President & CEO**Cognigenics, Inc.** (In-Person)**Categorical Listings:** CNS-Neurological, Genomics, Platform Technology**Location:** Eagle, Idaho United States**Year Established:** 2021 **Website:** www.cognigenics.io**Corporate Partners:** None**Funds Raised:** \$1.6M in Angel and Seed funding.**Presenter:** Tracy Brandmeyer, PhD, MSc, CTO**Crossject SA (Euronext:ALCJ)** (In-Person)**Categorical Listings:** Drug Delivery, Neurology**Location:** Dijon, France**Year Established:** 2001 **Website:** www.crossject.com**Corporate Partners:** BARDA**Funds Raised:** €180M**Presenter:** Patrick Alexandre, CEO

Additional Presenting Company Profiles

Conference Update

Dscilab Co., Ltd. (In-Person)

Categorical Listings: Cardiovascular, Drug Delivery, Orphan-Rare Disease

Location: Shanghai, China

Year Established: 2022 **Website:** www.dscilaboratory.com

Corporate Partners: Fosun Pharma

Funds Raised: \$6M in 2022, more than \$8M in 2023.

Presenter: Dan (Danielle) Chen, PhD, VP

Espervita Therapeutics (In-Person)

Categorical Listings: Endocrine-Metabolic, Fibrosis, Oncology

Location: Plymouth, Michigan United States

Year Established: 2018 **Website:** www.espervita.com

Corporate Partners: Seeking corporate partners.

Funds Raised: \$6M to date.

Presenter: Spencer Heaton, MD, MBA, CEO

GeneLancet Biosciences, Inc. (In-Person)

Categorical Listings: Gene-Cell Therapy, Infectious Disease, Platform Technology

Location: Doylestown, Pennsylvania United States

Year Established: 2019 **Website:** www.genelancetbio.com

Corporate Partners: Blumberg Institute on LgRNA-CRISPR treatment of chronic hepatitis B.

Funds Raised: SBIR (\$0.3M), R21(\$0.3M, R33 potentially >\$1M), \$0.3M (private fund).

Presenter: Minghong Zhong, PhD, CEO

ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX:1541) (In-Person)

Categorical Listings: Antibodies, Immuno-oncology, Oncology

Location: Shanghai, China

Year Established: 2015 **Website:**

cn.immuneonco.com/science/index.html#STARDTPlatform

Corporate Partners: INP

Funds Raised: Approximately \$259M since establishment, with over HK\$10B in market cap.

Presenter: Wenzhi Tian, MD, PhD, Chairman, CEO & CSO

iQure Pharma (In-Person)

Categorical Listings: CNS-Neurological, Neuropathy, Platform Technology

Location: Princeton, New Jersey United States

Year Established: 2019 **Website:** www.iquirepharma.com

Corporate Partners: INP

Funds Raised: 2023 A2 \$1.8M oversubscribed, 2022 A1 \$1.1M; 2021-2019 Founders \$400K.

Presenter: Paul Zolnierczyk, MSc, CEO

Lactiga US, Inc. (In-Person)

Categorical Listings: Antibodies, Immunology, Orphan-Rare Disease

Location: North Brunswick Township, New Jersey United States

Year Established: 2021 **Website:** www.lactiga.com

Corporate Partners: iNP

Funds Raised: \$1.7M

Presenter: Rikin Mehta, PharmD, Co-Founder & CEO

Lynk Pharmaceuticals Co., Ltd. (In-Person)

Categorical Listings: Autoimmune, CNS-Neurological, Dermatology

Location: Hangzhou, China

Year Established: 2018 **Website:** www.lynkpharma.com

Corporate Partners: The company's lead compound LNK01001 is partnered in greater China with Simcere for two indications.

Funds Raised: Completed C2 funding round in 2023. C round financing of ¥322M.

Presenter: Michael L. Vazquez, PhD, Co-Founder & Head of Chemistry

MEKanic Therapeutics, Inc. (In-Person)

Categorical Listings: Drug Discovery, Oncology

Location: Minneapolis, Minnesota United States

Year Established: 2015 **Website:** www.mekanic.com

Corporate Partners: Just beginning to explore dual registration and distribution partnerships in Asia.

Funds Raised: \$10M+ in NIH grants, \$3M in Series A.

Presenter: Judith (Judy) Leopold, PhD, CSO

Modulus Therapeutics, Inc. (In-Person)

Categorical Listings: Autoimmune, Functional Genomics, Gene-Cell Therapy

Location: Seattle, Washington United States

Year Established: 2020 **Website:** www.modulustherapeutics.com

Corporate Partners: Undisclosed pharma collaborators.

Funds Raised: \$6M

Presenter: Max Darnell, PhD, CEO

NGGT Inc. (In-Person)

Categorical Listings: Biomanufacturing, Gene-Cell Therapy, Orphan-Rare Disease

Location: Sacramento, California United States

Year Established: 2020 **Website:** www.nggtbio.com

Corporate Partners: INP

Funds Raised: \$84M

Presenter: Lixin Jiang, PhD, Co-Founder & CEO

Pattern Computer (In-Person)

Categorical Listings: Artificial Intelligence (AI), Diagnostics, Drug Discovery

Location: Friday Harbor, Washington United States

Year Established: 2015 **Website:** www.patterncomputer.com

Corporate Partners: Partners include: Fred Hutchinson Cancer Center; Lawrence Berkeley and Los Alamos National Laboratories; Limerick Digital Cancer Research Centre; Karolinska Institutet; University of Washington; UC San Diego; Al.Hamburg.

Funds Raised: Over \$33M to date, in six rounds; current B Round is for \$40M, with \$11M in.

Presenter: Mark Anderson, PhD, MS, Chair & CEO

Conference Update

RND Pharmaceuticals Inc. (In-Person)

Categorical Listings: Autoimmune, Gastrointestinal, Gene-Cell Therapy

Location: New York, New York United States

Year Established: 2023 **Website:** www.rndpharmaceuticals.com

Corporate Partners: RND-101: Cell4Cure (Sweden), and RND-103: not disclosed yet.

Funds Raised: RND-101 and RND-103 were developed by the originator, up to the clinical stage at an investment of ~\$30M each.

Presenter: Ramon Mohanlal, MD, PhD, CEO

Sagmos Therapeutics (In-Person)

Categorical Listings: Cardiovascular, Mitochondrial Therapeutic, Renal

Location: Greenwich, Connecticut United States

Year Established: 2016 **Website:** INP

Corporate Partners: Discussions ongoing.

Funds Raised: Approximately \$10M.

Presenter: Anna Kazanchyan, MD, CEO

Sapphiros Ai Bio (In-Person)

Categorical Listings: Gene-Cell Therapy, Regenerative Medicine

Location: Boston, Massachusetts United States

Year Established: 2021 **Website:** www.sapphiros.ai

Corporate Partners: PPD is the company's clinical services partner, Patheon is its CDMO and it is partnered with Regenity to develop innovative bio absorbable scaffolds for select therapeutic applications.

Funds Raised: The company is a spin out from a KKR funded organization.

Presenter: Robin Y. Smith, CEO

SHIFTBIO INC. (In-Person)

Categorical Listings: Drug Discovery, Fibrosis, Gene-Cell Therapy

Location: Seoul, South Korea

Year Established: 2020 **Website:** www.shiftbio.net

Corporate Partners: RoosterBio (CMC), Dassault Systèmes (Collaborative Research).

Funds Raised: Attracted private investment of \$6M (2023).

Presenter: Gi-Hoon Nam, MD, PhD, Co-Founder & CEO

Sinaptica Therapeutics Inc. (In-Person)

Categorical Listings: CNS-Neurological, Machine Learning, Neurology

Location: Cambridge, Massachusetts United States

Year Established: 2021 **Website:** www.sinapticatx.com

Corporate Partners: The company signed an LOI with a hardware partner for developing its systems but is open to strategic partnerships as well.

Funds Raised: All previous Ph2 funding was non-dilutive, funded by grants. Recently closed a \$1.5M Seed (SAFE) round oversubscribed.

Presenter: Ken Mariash, CEO

Trilo Therapeutics (In-Person)

Categorical Listings: Antibodies, Drug Discovery, Oncology

Location: San Francisco, California United States

Year Established: 2017 **Website:** www.trilotx.com

Corporate Partners: The company has been selected in pharmaceutical sponsored competitions for startups as winner (AbbVie, 2019; Amgen, 2020) or finalist (BMS, 2023).

Funds Raised: More than \$2.3M to date from Angel investors and NSF grant.

Presenter: Kurt Gish, PhD, President & CEO

UgeneX Therapeutics (In-Person)

Categorical Listings: Gene-Cell Therapy, Ophthalmic

Location: Shanghai, China

Year Established: 2021 **Website:** INP

Corporate Partners: Fosun Pharma

Funds Raised: Approximately \$6M

Presenter: Sijie Sun, PhD, Executive President

VacV Biotherapeutics Limited (In-Person)

Categorical Listings: Immuno-oncology, Oncology, Platform Technology

Location: London, United Kingdom

Year Established: 2022 **Website:** www.vacvbx.com

Corporate Partners: No corporate partners yet.

Funds Raised: \$10M to date. \$3M in equity and \$7M in grants.

Presenter: Glyn Edwards, MBA, Executive Chair

Variant Bio, Inc. (In-Person)

Categorical Listings: Bioinformatics, Drug Discovery, Genomics

Location: Seattle, Washington United States

Year Established: 2018 **Website:** www.variantbio.com

Corporate Partners: INP

Funds Raised: \$130M since November 2018 - Seed round in 2018, \$25M Series A in 2020, \$105M Series B in 2021.

Presenter: Andrew Farnum, CEO

Westlake Genetech (In-Person)

Categorical Listings: Artificial Intelligence (AI), Drug Delivery, Gene-Cell Therapy

Location: Hangzhou, China

Year Established: 2021 **Website:**

www.westlakegenetech.com/en/index.html

Corporate Partners: Westlake Genetech is looking to license AAV variants targeting muscles, CNS, heart, and immune cells. The company is also looking for the co-development of an early-stage pipeline.

Funds Raised: \$15M since 2021.

Presenter: Lijia Ma, PhD, Scientific Founder

Zenon Biotech (In-Person)

Categorical Listings: Fibrosis, Oncology, Platform Technology

Location: Woburn, Massachusetts United States

Year Established: 2020 **Website:** www.zenonbiotech.com

Corporate Partners: Zenon is actively seeking institutional investors and strategic partners.

Funds Raised: \$5M

Presenter: David Lagares, PhD, MSc, Founder & CEO

DigiMed Presenting Companies**Ultra Sight** (In-Person)

Categorical Listings: Artificial Intelligence (AI), Cardiovascular, Diagnostics

Location: Ness Ziona, Israel

Year Established: 2018 **Website:** www.ultrasight.com

Corporate Partners: EchoNous, Selvas, Healcerion, HeartNexus and Clarius are UltraSight's device manufacturer partners.

Funds Raised: \$22.2M funds to date.

Presenter: Davidi Vortman, CEO

YunQuan Biological Technology (Beijing) Co., Ltd. (In-Person)

Categorical Listings: Artificial Intelligence (AI), Autoimmune, Drug Discovery

Location: Beijing, China

Year Established: 2020 **Website:** www.longtengjingyun.com

Corporate Partners: Collaborated with Professor Haiyan Liu from the University of Science and Technology of China.

Funds Raised: To raise \$1B in financing in 2024.

Presenter: Minghui Dong, PhD, CEO

SEED Presenting Companies**Dionysus Digital Health, Inc** (In-Person)

Categorical Listings: Epigenetics, Machine Learning, Women's Health

Location: San Diego, California United States

Year Established: 2020 **Website:** www.dionysushealth.com

Corporate Partners: Several on-going discussions with female health clinics.

Funds Raised: Approximately \$950K pre-Seed, and \$415K from NIH RADx (Rapid Acceleration of Diagnostics).

Presenter: Andrea Cubitt, PhD, CEO

Elenae Therapeutics, Inc. (In-Person)

Categorical Listings: Cardiovascular, Fibrosis, Ophthalmic

Location: Berkeley, California United States

Year Established: 2021 **Website:** www.elenaetherapeutics.com

Corporate Partners: INP

Funds Raised: \$1.25M pre-Seed Angel investment.

Presenter: Anders Naar, PhD, CEO

Embold Therapeutics, Inc. (In-Person)

Categorical Listings: CNS-Neurological, Drug Discovery, Platform Technology

Location: Redwood City, California United States

Year Established: 2023 **Website:** www.emboldtx.com

Corporate Partners: The company does not have corporate partners currently.

Funds Raised: Minimal - Internally funded.

Presenter: Gjalt Huisman, PhD, CEO

SEED Presenting Companies (cont'd)**Eugit Therapeutics Inc** (In-Person)

Categorical Listings: Gene-Cell Therapy, Inflammation, Platform Technology

Location: San Carlos, California United States

Year Established: 2022 **Website:** www.eugittx.com

Corporate Partners: None

Funds Raised: \$500K in June 2022, \$200K in October 2022.

Presenter: Nizar Batada, PhD, CEO

Narwhal Bio Inc. (In-Person)

Categorical Listings: Gene-Cell Therapy, Immuno-oncology, Regenerative Medicine

Location: San Diego, California United States

Year Established: 2021 **Website:** www.narwhal.bio

Corporate Partners: INP

Funds Raised: INP

Presenter: Behrad Azimi, PhD, Co-Founder & CEO

Novel Biotechnology Inc. (Virtual)

Categorical Listings: Biomanufacturing, Gene-Cell Therapy, Platform Technology

Location: Woodbridge, Canada

Year Established: 2021 **Website:** www.novelbiologics.com

Corporate Partners: Working with 8 potential partners to deploy the technology.

Funds Raised: \$1.7M so far and planning to raise another \$1.5M to \$2M in next 6-12 months.

Presenter: Pankaj Khanna, MSc, President

Papillon Biosciences, Inc. (Virtual)

Categorical Listings: Drug Delivery, Endocrine-Metabolic, Platform Technology

Location: Pasadena, California United States

Year Established: 2022 **Website:** www.papillonbio.com

Corporate Partners: PapillonBio is interested in exploring partnerships with pharmaceutical companies interested in the development of novel treatments for diabetes.

Funds Raised: Seeking to raise Seed round funding. To date funded by management team.

Presenter: Matthew J. Pfeffer, EVP & CFO

TMAB Therapeutics, Inc. (In-Person)

Categorical Listings: Antibodies, Oncology, Orphan-Rare Disease

Location: Houston, Texas United States

Year Established: 2023 **Website:** www.nandilifesciences.com

Corporate Partners: Texas Medical Center (TMC) and TMC Accelerator for Cancer Therapeutics.

Funds Raised: INP

Presenter: Tinashe Chandauka, CEO